Navigation Links
Hepatitis C may increase deaths from both liver-related and other diseases

[EMBARGOED FOR JULY 18, 2012] In a long-term study of people infected with the hepatitis C virus (HCV), researchers found increased deaths from both liver-related and non-liver related diseases in patients with active infections who had not cleared their infection.

The study, published in the Journal of Infectious Diseases and available online, found increased mortality in patients with chronic HCV infectionthat is, with detectable levels of HCV genetic material, or RNA, in their bloodsuggesting that chronic HCV infections, even in people who have no symptoms, can lead to increased mortality from liver disease or a variety of other causes. The findings highlight the importance of people getting tested for HCV antibodies and for active HCV infectionand of evaluating patients for antiviral treatment when they are found to have an active HCV infection, even when they feel well.

HCV infects more than 170 million people globally and has been shown to cause such liver diseases as cirrhosis and hepatocellular carcinoma. Many infected patients have no symptoms and are not aware of infection until after irreversible liver disease has occurred. In addition, several diseases not related to the liver have been linked to HCV. However, nearly two-thirds of patients can be cured of their HCV infection with currently available antiviral therapy.

Chien-Jen Chen, ScD, and researchers from the Genomic Research Center in Taipei, Taiwan, enrolled more than 23,000 adults in Taiwan in their study and followed them from 1991 to 2008. Blood samples were collected at study entry and at follow-up health examinations. Researchers found increased mortality from liver- and non-liver-related diseasesincluding cancers of the esophagus, prostate, and thyroid, as well as circulatory and renal diseasesamong those infected with HCV. Mortality was higher in HCV-infected participants with detectable serum levels of HCV RNA, indicating they had active infections; subjects with previous infections who only had HCV antibodies, but not HCV RNA, in their blood did not have increased mortality on follow-up.

According to Dr. Chen, "The findings implied that the serum HCV RNA level is an important marker for clinical decisions in the management of HCV-infected patients." Dr. Chen suggested that HCV-infected patients may benefit from treatment with antiviral and immunomodulating agents to promote viral clearance.

The investigators concluded that their findings have significant implications for clinical practice and public healthnamely, that individuals seropositive for HCV RNA should be followed intensively and urged to be evaluated for antiviral therapy. In addition, they noted, testing to determine serum HCV RNA level by a sensitive assay is essential for clinical management of HCV-infected patients.

Dr. Chen and his colleagues cautioned that some non-liver-related diseases are too rare to accurately determine their risk in connection with HCV infection. They suggested that a collaborative study with a large sample size would be needed in order to further investigate the full spectrum of diseases associated with HCV.

In an accompanying editorial, Kenrad E. Nelson, MD, of Johns Hopkins University in Baltimore, noted that overall mortality was significantly increased from liver-related and other causes compared to uninfected patients from the same communities in the study. The findings indicate that, although some who are infected with HCV can cure their infection without treatment, most people who are infected and who have no symptoms develop chronic infections and are at increased risk of death from HCV, Dr. Nelson said.

Many patients with HCV infection go undiagnosed, and among those whose infection is detected, "few are medically evaluated and effectively treated," Dr. Nelson added. Although treatment for HCV infection is improving dramatically, he noted, a significant reduction in HCV-related mortality will require that screening measures are greatly expanded.

Fast Facts:

  1. Overall mortality in patients infected with hepatitis C virus (HCV) was significantly increased from both liver-related and other diseases compared to uninfected patients from the same communities.
  2. Compared to people who had never been infected with HCV, mortality was higher in HCV-infected patients with detectable levels of HCV RNA in their blood on follow-up, but not in patients with inactive infectionsthose who were positive for HCV antibodies but whose blood was free of HCV RNA.
  3. Diseases not related to the liver that were observed in this study included cancers of the esophagus, prostate, and thyroid, and circulatory and renal diseases.
  4. Most people with chronic HCV infection don't know they are infected because the infection is often without symptoms. However, chronic HCV can be curable with treatment, so people should be screened and considered for treatment if they have chronic HCV infection.


Contact: Sky Opila
Infectious Diseases Society of America

Related medicine news :

1. Milk Thistle of Little Help Against Hepatitis C: Study
2. Helper T cells, not killer T cells, might be responsible for clearing hepatitis A infection
3. Hepatitis C Virus Levels Higher in Certain Injection Drug Users
4. Current and former smokers at risk for recurrent hepatitis post-liver transplantation
5. EASL-AASLD Special Conference on Therapy of Hepatitis C
6. Many Homeless May Harbor Hepatitis C
7. Hepatitis B Infection Rates in U.S. Higher Than Thought
8. 16th-century Korean mummy provides clue to hepatitis B virus genetic code
9. Hepatitis C Causing Liver Damage in Greater Numbers: Study
10. Test Baby Boomers for Hepatitis C, Says CDC
11. Gastroenterology special issue focuses on new directions of viral hepatitis care and research
Post Your Comments:
(Date:12/1/2015)... Illinois (PRWEB) , ... December 01, 2015 , ... ... and share medical images have been lifted as IMAGE Information Systems launches MED-TAB™ ... Society of North America Annual Meeting from November 29 to December 4, 2015. ...
(Date:12/1/2015)... ... December 01, 2015 , ... For many X-rays taken at ... accurate interpretation by the radiologist. The marking utensils are so small, however, they ... found a way to alleviate this problem. , He developed the patent-pending MARK ...
(Date:12/1/2015)... CA (PRWEB) , ... December 01, 2015 , ... ... Health Center of Excellence (BHCOE) today announced that the organization has awarded Education ... San Francisco, with a Distinguished Award. The award celebrates exceptional special needs providers ...
(Date:12/1/2015)... ... ... Lutronic, a leading innovator of aesthetic and medical laser and energy-based technology, announced ... the United States. Clarity is a Superior Dual Wavelength Platform which combines two ... platform that is easy to own and operate. , For over a decade, ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... XTC ... selected 10 semi-finalists to head to Las Vegas for CES 2016, the world’s largest ... CEO of Consumer Technology Association Gary Shapiro, Founding Partner of Pacific Investments Veronica Serra, ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... Dec. 1, 2015   Nottingham Spirk , ... announced the publication of a free whitepaper ... Medical Market". The whitepaper gives medical product companies, ... penetrating this lucrative segment. Nottingham Spirk ... to manage their own health, save money (i.e., ...
(Date:12/1/2015)... BOULDER, Colo. , Dec. 1, 2015 ... ARRY ) today announced that its Chief ... present at the Oppenheimer Annual Healthcare Conference ... to participate in the conference through a ... , --> ...
(Date:12/1/2015)... BANGALORE, India and ... (NASDAQ, TASE: MYL) today announced that it expects to ... for developing country markets funded by international donors, TLE400 ... + Efavirenz 400 mg) for $99 per patient, per ... (CHAI) to develop TLE400. The significantly reduced price could ...
Breaking Medicine Technology: